期刊文献+

调节高密度脂蛋白治疗的研究进展 被引量:2

Progress in Treatment for Regulating High-density Lipoprotein
下载PDF
导出
摘要 高密度脂蛋白的降低和功能失调是动脉粥样硬化的一个重要原因。一般认为,高密度脂蛋白水平与冠心病呈负相关,其机制包括胆固醇的逆向转运、抗氧化、抗血栓、调节内皮功能等。但是,由于高密度脂蛋白组成成分复杂,调节其功能比升高其总体水平更重要。目前调节高密度脂蛋白的治疗主要有改变生活方式、药物治疗以及新近的生物制剂,以期降低心血管疾病的发病率及病死率。 Reduced high-density lipoprotein and functional disorder is a vital cause of artherosclerosis. It's generally acknowledged that high-density lipoprotein is negatively correlated with cardiovascular heart disease, its mechanisms include reverse cholesterol transport, antioxidation, antithrombotic, and regulating endothelial function etc.. However, the composition of high-density lipoprotein is so complex that it's more important to reg- ulate its function than to elevate its level. So far, the therapies include changing lifestyle, medication, and recent biological agent, hoping to lower the morbidity and mortality of cardiovascular disease.
作者 李薇 王岚峰
出处 《医学综述》 2012年第19期3234-3237,共4页 Medical Recapitulate
关键词 高密度脂蛋白 冠状动脉粥样硬化性心脏病 血脂 High-density lipoprotein Coronary atherosclerotic heart disease Blood lipid
  • 相关文献

参考文献36

  • 1Barter P,Gotto AM,LaRosa JC,et al.HDL cholesterol,very lowlevels of LDL cholesterol,and cardiovascular events[J].N Engl JMed,2007,357(13):1301-1310. 被引量:1
  • 2Expert Panel on Detection,Evaluation,and Treatment of HighBlood Cholesterol in Adults.Executive Summary of The Third Re-port of The National Cholesterol Education Program(NCEP)ExpertPanel on Detection,Evaluation,And Treatment of High Blood Cho-lesterol In Adults(Adult Treatment PanelⅢ)[J].JAMA,2001,16,285(19):2486-2497. 被引量:1
  • 3Soudijn W,van Wijngaarden I,Ijzerman AP.Nicotinic acid recep-tor subtypes and their ligands[J].Med Res Rev,2007,27(3):417-433. 被引量:1
  • 4Taylor AJ,Sullenberger LE,Lee HJ,et al.Arterial biology for theinvestigation of the treatment effects of reducing cholesterol(ARBI-TER)2:a double-blind,placebo-controlled study of extended-re-lease niacin on atherosclerosis progression in secondary preventionpatients treated with statins[J].Circulation,2004,110(23):3512-3517. 被引量:1
  • 5Taylor AJ,Lee HJ,Sullenberger LE.The effect of 24 months ofcombination statin and extended-release niacin on carotid intima-media thickness:ARBITER 3[J].Curr Med Res Opin,2006,22(11):2243-2250. 被引量:1
  • 6Vosper H.Extended release niacin-laropiprant in patients with hy-percholesterolemia or mixed dyslipidemias improves clinical param-eters[J].Clin Med Insights Cardiol,2011,5:85-101. 被引量:1
  • 7Masana L.Pitavastatin-from clinical trials to clinical practice[J].Atheroscler Suppl,2010,11(3):15-22. 被引量:1
  • 8Fruchart JC.Peroxisome proliferator-activated receptor-alpha acti-vation and high-density lipoprotein metabolism[J].Am J Cardiol,2001,88(12A):24N-29N. 被引量:1
  • 9Benatar JR,Stewart RA.Is it time to stop treating dyslipidaemiawith fibrates?[J].N Z Med J,2007,120(1261):U2706. 被引量:1
  • 10Vaisar T,Pennathur S,Green PS,et al.Shotgun proteomics impli-cates protease inhibition and complement activation in the antiin-flammatory properties of HDL[J].J Clin Invest,2007,117(3):746-756. 被引量:1

同被引文献21

引证文献2

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部